文献速递肝病消化道肿瘤与早癌

基于GPC3的环状RNA疫苗通过激活适应性免疫抑制肝细胞癌进展

GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses.
PubMed 文献 · Hepatology · 2025-11-07

该研究设计了一种编码GPC3的环状RNA疫苗(circGPC3),在肝癌中评估其疗效与安全性。circGPC3疫苗能持续产生抗原,克服传统mRNA疫苗的局限,产生更强更持久的抗肿瘤免疫应答。联合TLR4激动剂可有效抑制肝癌进展,机制涉及增强免疫蛋白酶体介导的抗原呈递及cDC1与CD8+ T细胞通过MHC-I通路的相互作用,从而重编程肿瘤微环境。

要点

  • circGPC3疫苗较mRNA疫苗具有更优的持续抗原生产和抗肿瘤免疫效果。
  • 联合TLR4激动剂可进一步增强免疫应答并抑制肝癌进展。
  • 机制涉及增强抗原呈递和cDC1-CD8+ T细胞相互作用。

核心结论

  • circGPC3癌症疫苗疗效优于mRNA癌症疫苗。
  • 联合TLR4激动剂可打破肝癌免疫耐受,是有前景的转化治疗策略。

研究设计与样本

  • 研究设计了编码GPC3的环状RNA疫苗,并在肝癌中评估其治疗疗效和安全性。
  • 采用多重免疫荧光、单细胞测序、空间转录组学和质谱流式技术表征小鼠肿瘤微环境。

主要发现

  • circGPC3疫苗能持续产生抗原,克服传统mRNA疫苗的固有局限。
  • circGPC3疫苗产生更强更持久的抗肿瘤免疫应答。
  • circGPC3疫苗联合TLR4激动剂有效抑制肝癌肿瘤进展。
  • 机制上,circGPC3疫苗显著增强免疫蛋白酶体介导的抗原呈递。
  • circGPC3疫苗通过MHC-I通路加强cDC1与CD8+ T细胞相互作用,促进适应性免疫启动并重编程肿瘤微环境。

临床怎么用

  • circGPC3疫苗联合TLR4激动剂可能作为肝癌的转化治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Messenger RNA (mRNA) vaccine is a promising approach for cancer therapy. However, the development of mRNA cancer vaccines encounters several challenges, including mRNA instability, inefficient delivery systems, and potential biosafety concerns. Addressing these issues requires optimizing mRNA design, developing novel delivery vectors, and enhancing immune responses. We aimed to develop a circular RNA (circRNA)-based cancer vaccine targeting tumor-associated antigen Glypican-3 (GPC3), a promising target in hepatocellular carcinoma (HCC), to improve antigen stability and anti-tumor immune responses. APPROACH AND RESULTS: We designed a circRNA-based vaccine encoding GPC3 for HCC and evaluated the therapeutic efficacy and safety of the circGPC3 vaccine. The circGPC3 vaccine demonstrated sustained antigen production, overcoming the inherent limitations of traditional mRNA vaccines and resulting in more potent and durable anti-tumor immune responses. In addition, we incorporated a Toll-like receptor 4 (TLR4) agonist as an adjuvant to further enhance immune responses. CircGPC3 vaccine plus TLR4 agonist effectively suppressed tumor progression in HCC. We employed multiplex immunofluorescence, single-cell sequencing, spatial transcriptomics, and mass cytometry to characterize the tumor microenvironment (TME) in mice following combination therapy and to elucidate the mechanism. Mechanistically, the circGPC3 vaccine significantly enhanced immunoproteasome-mediated antigen presentation and strengthened the interaction between cDC1 and CD8 + T cells through the MHC-I pathway, therefore facilitating a more effective initiation of adaptive immune responses and reprogramming TME. CONCLUSIONS: The circGPC3 cancer vaccine demonstrated superior efficacy compared with the mRNA cancer vaccine. When further combined with a TLR4 agonist, it disrupted immune tolerance in HCC, offering a promising translational treatment strategy for HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Jiang Y, Li Y, Wu T, et al. GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses. Hepatology. 2025. PMID: 41201153. doi:10.1097/HEP.0000000000001605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。